CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma

BACKGROUND: In the past few years, immunotherapies of hepatocellular carcinoma (HCC) targeting programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1), have achieved durable clinical benefits. However, only a fraction of HCC patients showed objective clinical res...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruonan, Wang, Jie, Du, Yu, Yu, Ze, Wang, Yihan, Jiang, Yixiao, Wu, Yixin, Le, Ting, Li, Ziqi, Zhang, Guoqiang, Lv, Lei, Ma, Haijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679996/
https://www.ncbi.nlm.nih.gov/pubmed/38007240
http://dx.doi.org/10.1136/jitc-2023-007529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679996/
https://www.ncbi.nlm.nih.gov/pubmed/38007240
http://dx.doi.org/10.1136/jitc-2023-007529

Ejemplares similares